Tag: ornithine transcarbamylase deficiency otc deficiency market share

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Size, Value And Growth Trends Through 2030

The landscape for ornithine transcarbamylase deficiency (OTC deficiency) has witnessed robust expansion lately, with projections indicating continued positive momentum. Starting at $0.89 billion in 2025, the market is expected to reach $0.95 billion by 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. Key factors contributing to this past growth trajectory include a scarcity of therapeutic interventions coupled with a substantial disease impact, heightened recognition of OTC deficiency in newborns, the early embrace of liver transplantation and specialized dietary approaches, intensified scientific inquiry into uncommon genetic conditions, and an increase in the incidence of complications linked to hyperammonemia.

The market for ornithine transcarbamylase deficiency (OTC deficiency) is poised for substantial expansion over the coming years, with projections indicating a rise to $1.23 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth trajectory is underpinned by several key factors, including the burgeoning pipeline of gene and mRNA-based therapeutic interventions, the enhanced accessibility of enzyme replacement and protein engineering solutions, a greater embrace of precision medicine strategies, escalating investments directed towards rare disease research, and the broadening reach of diagnostic testing and genetic screening initiatives. Key developments shaping the forecast period involve a heightened adoption of gene therapy for OTC deficiency, a concentrated effort on tailored and targeted therapeutic strategies, amplified awareness concerning early detection via genetic testing, a surge in demand for enzyme replacement and protein engineering treatments, and an increasing clinical priority placed on monitoring and managing ammonia levels.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Development Factors: Which Trends Are Supporting Demand?

The expansion of the ornithine transcarbamylase deficiency market is anticipated to be fueled by the increasing interest in gene therapies. Gene therapy, a medical intervention focused on modifying an individual’s genetic makeup to combat or avert illnesses, is seeing heightened demand due to the escalating incidence of genetic conditions. These inherited disorders frequently possess few available treatments, positioning gene therapy as an attractive strategy to tackle the underlying genetic issue rather than merely alleviating symptoms. Ornithine transcarbamylase deficiency serves as a prime example of gene therapy’s potential, as it aims to rectify the specific genetic defect affecting the urea cycle, thereby enabling a precise intervention to re-establish metabolic balance and avert the dangerous buildup of ammonia. Illustrating this trend, data from the American Society of Gene & Cell Therapy indicated that in the fourth quarter of 2023, the number of gene therapies progressing through Phase III clinical trials saw a 10% surge compared to the preceding quarter, representing the first upward movement since the third quarter of 2022. Consequently, the rising adoption and development of gene therapies are directly contributing to the anticipated growth within the ornithine transcarbamylase deficiency market.

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segment Performance And Strategic Opportunities

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Transformation Trends: Which Innovations Are Driving Change?

Within the ornithine transcarbamylase deficiency (OTC Deficiency) market, key players are directing their efforts toward pioneering novel treatments, including mRNA therapeutics, with the aim of improving treatment outcomes and targeting the root genetic basis of OTC deficiency. The category of mRNA therapeutics functions by employing messenger RNA to direct cellular mechanisms to generate particular proteins that serve therapeutic functions, utilizing the body’s inherent protein production systems to address conditions ranging from inherited disorders to infections and malignancies. As an illustration, in June of 2023, Arcturus Therapeutics Holdings Inc., a biotechnology enterprise situated in the United States, was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for ARCT-810, its investigational mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency. This specific designation is established to expedite the drug’s progression through development and regulatory review, potentially facilitating increased engagement with the FDA and a prioritized examination. ARCT-810 has been engineered to empower individuals diagnosed with OTC deficiency, a disorder affecting the urea cycle, to generate a functional OTC enzyme within their liver cells, thereby confronting the fundamental cause of the ailment and potentially leading to an enhanced standard of living.

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Access The Complete Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Largest Region By Revenue And Market Share

North Americawas the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Increase Between 2026 And 2030?

The market for ornithine transcarbamylase deficiency (otc deficiency) has seen substantial growth over recent years. It is anticipated to expand from $0.89 billion in 2025 to $0.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. This historical growth can be ascribed to several factors, including the limited availability of treatment options and a high disease burden, increasing awareness of otc deficiency in neonates, the early adoption of liver transplant and dietary management strategies, growing research efforts into rare genetic disorders, and a rising prevalence of complications linked to hyperammonemia.

The ornithine transcarbamylase deficiency (otc deficiency) market is anticipated to experience robust growth in the coming years. Its valuation is projected to reach $1.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period stems from a broadening pipeline of gene and mRNA-based therapies, enhanced availability of enzyme replacement and protein engineering solutions, widespread adoption of precision medicine approaches, augmented investments in rare disease research, and the broader implementation of diagnostic testing and genetic screening programs. Prominent trends for the forecast period include the increasing embrace of gene therapy for otc deficiency, a heightened emphasis on personalized and targeted treatment methods, enhanced understanding of early diagnosis through genetic testing, an escalating demand for enzyme replacement and protein engineering therapies, and a greater clinical focus on ammonia level monitoring and management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Are The Main Drivers Accelerating The Growth Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The increasing need for gene therapies is projected to fuel the expansion of the ornithine transcarbamylase deficiency market moving forward. Gene therapy refers to a therapeutic approach or technique focused on altering or manipulating an individual’s genetic material to address or prevent diseases. The heightened demand for gene therapies stems from the growing prevalence of genetic disorders, as these conditions frequently have limited treatment choices, and gene therapy presents a promising method to target the root cause rather than merely managing symptoms. Ornithine transcarbamylase deficiency exemplifies the potential of gene therapies by rectifying the genetic mutation that disrupts the urea cycle, enabling precise treatment to restore metabolic function and avert harmful ammonia accumulation. For instance, in January 2024, data from the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, indicated that the count of gene therapies in Phase III during Q4 2023 rose by 10% compared to the preceding quarter, representing the first increase since Q3 2022. Consequently, the escalating demand for gene therapies is a significant impetus for the growth of the ornithine transcarbamylase deficiency market.

What Are The Core Segment Classifications In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

Which Trends Are Supporting The Evolution Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Prominent companies active in the orlistat market are crafting innovative items, such as weight loss drugs, to boost personal hygiene and comfort by leveraging advanced technology and design. A weight loss drug is defined as a medicine formulated to assist people in decreasing their body weight by curbing appetite, boosting metabolism, or inhibiting fat absorption. As an illustration, in November 2023, Eli Lilly and Company, a US-based pharmaceutical enterprise, secured US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide) injection, which is a novel weight loss medication. This treatment represents the sole and initial approved option that stimulates two incretin hormone receptors, GIP and GLP-1, thereby tackling a fundamental reason behind surplus weight. Zepbound is prescribed for utilization as an addition to a lower-calorie diet and increased physical exercise for long-term weight management in adults suffering from obesity (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) and possess at least one associated weight condition.

Which Industry Players Are Present In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Access The Complete Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Which Region Holds The Largest Share In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp

Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company

Oryzanol Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Orthobiologics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Auditing Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Compare Between 2026 And 2030?

The market size for ornithine transcarbamylase deficiency (otc deficiency) has seen substantial growth over recent years. It is forecast to rise from $0.89 billion in 2025 to $0.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the preceding period can be ascribed to several factors, including limited therapeutic options and a high disease burden, increasing awareness of otc deficiency among neonates, the early adoption of liver transplantation and dietary management techniques, a rise in research pertaining to rare genetic disorders, and the growing incidence of hyperammonemia-related complications.

The ornithine transcarbamylase deficiency (otc deficiency) market size is anticipated to demonstrate strong growth in the coming years, with projections indicating it will reach $1.23 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period can be attributed to an expanding pipeline of gene and mRNA-based therapies, increasing availability of enzyme replacement and protein engineering solutions, a growing adoption of precision medicine approaches, rising investments in rare disease research, and the expansion of diagnostic testing and genetic screening programs. Key trends expected over this period include a rising adoption of gene therapy for otc deficiency, an increasing focus on personalized and targeted treatment approaches, growing awareness about early diagnosis through genetic testing, rising demand for enzyme replacement and protein engineering therapies, and an increasing clinical emphasis on ammonia level monitoring and management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Key Drivers Are Fueling The Growth Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The ornithine transcarbamylase deficiency market is projected to experience growth driven by the rising demand for gene therapies. Gene therapy involves a medical approach that alters or manipulates a person’s genetic material to either treat or prevent diseases. This heightened demand for gene therapies is a result of the increasing prevalence of genetic disorders, as these conditions frequently have limited therapeutic options, and gene therapy presents a promising strategy to address the fundamental cause rather than merely managing symptoms. Ornithine transcarbamylase deficiency exemplifies the potential of gene therapies by correcting the genetic mutation that interferes with the urea cycle, thereby enabling a targeted treatment to restore metabolic function and prevent the accumulation of toxic ammonia. For example, in January 2024, the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, stated that in Q4 2023, the quantity of gene therapies in Phase III grew by 10% from the preceding quarter, representing the first increase since Q3 2022. Hence, the escalating demand for gene therapies is propelling the growth of the ornithine transcarbamylase deficiency market.

What Segment Categories Shape The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segment Landscape?

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

What Trends Are Influencing The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Leading firms within the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on creating novel treatments, including mRNA therapeutics, to improve the effectiveness of care and target the fundamental genetic origin of OTC deficiency. These mRNA-based therapies represent a category of medical interventions utilizing messenger RNA (mRNA) to direct cells in synthesizing particular proteins for therapeutic aims. Such treatments harness the body’s inherent protein production mechanisms to combat various conditions, encompassing genetic disorders, infectious diseases, and different forms of cancer. A notable example occurred in June 2023, when Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, their experimental mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency. This designation aims to expedite the drug’s development and regulatory review pathway, potentially providing advantages like increased engagement with the FDA and expedited review. The design of ARCT-810 intends to allow individuals suffering from OTC deficiency, which is a urea cycle disorder, to generate a functional OTC enzyme within their liver cells, thereby targeting the root cause of the ailment and potentially enhancing their overall quality of life.

Who Are The Companies Operating Across The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Value Chain?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Get The Full Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Which Region Represents The Largest Share Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company

Oryzanol Market Report 2026

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Orthobiologics Market Report

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Auditing Services Market Report

https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Evolve From 2026 To 2030?

The market size for ornithine transcarbamylase deficiency (otc deficiency) has experienced robust growth in recent years. It is projected to expand from $0.89 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to several factors, including limited treatment options and a high disease burden, increasing awareness of otc deficiency in neonates, early adoption of liver transplant and dietary management, a surge in research for rare genetic disorders, and the rising prevalence of hyperammonemia-related complications.

The market for ornithine transcarbamylase deficiency (OTC deficiency) is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $1.23 billion, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as an expanding array of gene and mRNA-based therapies, greater access to enzyme replacement and protein engineering solutions, an increase in the use of precision medicine, heightened investments in research for rare diseases, and the broadening of diagnostic testing and genetic screening initiatives. Key developments expected during this timeframe involve a surge in the adoption of gene therapy for OTC deficiency, a stronger emphasis on individualized and targeted treatment strategies, increased public understanding of early diagnosis via genetic testing, a growing need for enzyme replacement and protein engineering treatments, and a heightened clinical focus on monitoring and managing ammonia levels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Major Drivers Are Influencing Demand In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The market for ornithine transcarbamylase deficiency is anticipated to expand, fueled by the increasing demand for gene therapies. Gene therapy is defined as a medical approach involving the modification or manipulation of an individual’s genetic material to either treat existing diseases or prevent their occurrence. This growing demand for gene therapies stems from the increasing incidence of genetic disorders, which frequently lack effective treatment options; gene therapy presents a hopeful method for tackling the underlying cause of these conditions instead of merely alleviating symptoms. Ornithine transcarbamylase deficiency serves as an illustration of gene therapies’ potential, as it can rectify the genetic mutation responsible for disrupting the urea cycle, enabling precise treatment aimed at restoring metabolic function and preventing the buildup of toxic ammonia. As an example, the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported in January 2024 that the quantity of gene therapies in Phase III trials saw a 10% increase in Q4 2023 compared to the prior quarter, marking the first such rise since Q3 2022. Consequently, the increasing need for gene therapies is propelling the expansion of the ornithine transcarbamylase deficiency market.

Which Segment Areas Are Covered In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Analysis?

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

Which Market Trends Are Creating New Opportunities In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Companies prominent in the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on developing novel treatments, such as mRNA therapeutics, to boost treatment effectiveness and address the fundamental genetic origin of OTC deficiency. mRNA therapeutics constitute a category of treatments that employ messenger RNA (mRNA) to direct cells to create specific proteins for therapeutic goals. These therapies capitalize on the body’s innate protein synthesis processes to treat conditions including genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. This designation seeks to hasten the drug’s development and evaluation process, potentially offering advantages like more frequent FDA interactions and a priority review. ARCT-810 is formulated to enable patients with OTC deficiency, a urea cycle disorder, to generate functional OTC enzyme in their liver cells, thereby resolving the underlying cause of the condition and possibly enhancing their quality of life.

Which Global Companies Are Actively Competing In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Read the full ornithine transcarbamylase deficiency (otc deficiency) market report here:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp

Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company

Oryzanol Global Market Report

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Orthobiologics Global Market Report

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Auditing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Evolve From 2026 To 2030?

The market size for ornithine transcarbamylase deficiency (otc deficiency) has experienced robust growth in recent years. It is projected to expand from $0.89 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to several factors, including limited treatment options and a high disease burden, increasing awareness of otc deficiency in neonates, early adoption of liver transplant and dietary management, a surge in research for rare genetic disorders, and the rising prevalence of hyperammonemia-related complications.

The market for ornithine transcarbamylase deficiency (OTC deficiency) is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $1.23 billion, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as an expanding array of gene and mRNA-based therapies, greater access to enzyme replacement and protein engineering solutions, an increase in the use of precision medicine, heightened investments in research for rare diseases, and the broadening of diagnostic testing and genetic screening initiatives. Key developments expected during this timeframe involve a surge in the adoption of gene therapy for OTC deficiency, a stronger emphasis on individualized and targeted treatment strategies, increased public understanding of early diagnosis via genetic testing, a growing need for enzyme replacement and protein engineering treatments, and a heightened clinical focus on monitoring and managing ammonia levels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Major Drivers Are Influencing Demand In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The market for ornithine transcarbamylase deficiency is anticipated to expand, fueled by the increasing demand for gene therapies. Gene therapy is defined as a medical approach involving the modification or manipulation of an individual’s genetic material to either treat existing diseases or prevent their occurrence. This growing demand for gene therapies stems from the increasing incidence of genetic disorders, which frequently lack effective treatment options; gene therapy presents a hopeful method for tackling the underlying cause of these conditions instead of merely alleviating symptoms. Ornithine transcarbamylase deficiency serves as an illustration of gene therapies’ potential, as it can rectify the genetic mutation responsible for disrupting the urea cycle, enabling precise treatment aimed at restoring metabolic function and preventing the buildup of toxic ammonia. As an example, the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported in January 2024 that the quantity of gene therapies in Phase III trials saw a 10% increase in Q4 2023 compared to the prior quarter, marking the first such rise since Q3 2022. Consequently, the increasing need for gene therapies is propelling the expansion of the ornithine transcarbamylase deficiency market.

Which Segment Areas Are Covered In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Analysis?

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

Which Market Trends Are Creating New Opportunities In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Companies prominent in the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on developing novel treatments, such as mRNA therapeutics, to boost treatment effectiveness and address the fundamental genetic origin of OTC deficiency. mRNA therapeutics constitute a category of treatments that employ messenger RNA (mRNA) to direct cells to create specific proteins for therapeutic goals. These therapies capitalize on the body’s innate protein synthesis processes to treat conditions including genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. This designation seeks to hasten the drug’s development and evaluation process, potentially offering advantages like more frequent FDA interactions and a priority review. ARCT-810 is formulated to enable patients with OTC deficiency, a urea cycle disorder, to generate functional OTC enzyme in their liver cells, thereby resolving the underlying cause of the condition and possibly enhancing their quality of life.

Which Global Companies Are Actively Competing In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Read the full ornithine transcarbamylase deficiency (otc deficiency) market report here:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp

Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company

Oryzanol Global Market Report

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Orthobiologics Global Market Report

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Auditing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Evolve From 2026 To 2030?

The market size for ornithine transcarbamylase deficiency (otc deficiency) has experienced robust growth in recent years. It is projected to expand from $0.89 billion in 2025 to $0.95 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to several factors, including limited treatment options and a high disease burden, increasing awareness of otc deficiency in neonates, early adoption of liver transplant and dietary management, a surge in research for rare genetic disorders, and the rising prevalence of hyperammonemia-related complications.

The market for ornithine transcarbamylase deficiency (OTC deficiency) is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $1.23 billion, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as an expanding array of gene and mRNA-based therapies, greater access to enzyme replacement and protein engineering solutions, an increase in the use of precision medicine, heightened investments in research for rare diseases, and the broadening of diagnostic testing and genetic screening initiatives. Key developments expected during this timeframe involve a surge in the adoption of gene therapy for OTC deficiency, a stronger emphasis on individualized and targeted treatment strategies, increased public understanding of early diagnosis via genetic testing, a growing need for enzyme replacement and protein engineering treatments, and a heightened clinical focus on monitoring and managing ammonia levels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp

What Major Drivers Are Influencing Demand In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

The market for ornithine transcarbamylase deficiency is anticipated to expand, fueled by the increasing demand for gene therapies. Gene therapy is defined as a medical approach involving the modification or manipulation of an individual’s genetic material to either treat existing diseases or prevent their occurrence. This growing demand for gene therapies stems from the increasing incidence of genetic disorders, which frequently lack effective treatment options; gene therapy presents a hopeful method for tackling the underlying cause of these conditions instead of merely alleviating symptoms. Ornithine transcarbamylase deficiency serves as an illustration of gene therapies’ potential, as it can rectify the genetic mutation responsible for disrupting the urea cycle, enabling precise treatment aimed at restoring metabolic function and preventing the buildup of toxic ammonia. As an example, the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported in January 2024 that the quantity of gene therapies in Phase III trials saw a 10% increase in Q4 2023 compared to the prior quarter, marking the first such rise since Q3 2022. Consequently, the increasing need for gene therapies is propelling the expansion of the ornithine transcarbamylase deficiency market.

Which Segment Areas Are Covered In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Analysis?

The ornithine transcarbamylase deficiency (otc deficiency) market covered in this report is segmented –

1) By Product Type: DTX-301, SEL-313, SHP-641, PRX-OTC

2) By Treatment Type: Gene Therapy, Liver Transplant, Dietary Management, Other Treatement Types

3) By Diagnosis: Genetic Testing, Ammonia Level Testing

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy, Intravenous Dosing Formulation

2) By SEL-313: Immune Tolerance-Inducing Therapy, Enzyme Replacement Therapy (ERT) Combination

3) By SHP-641: Small Molecule Therapy, mRNA-Based Therapeutic Approach

4) By PRX-OTC: Recombinant Enzyme Replacement Therapy, Protein Engineering-Based Therapy

Which Market Trends Are Creating New Opportunities In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Companies prominent in the ornithine transcarbamylase deficiency (OTC Deficiency) market are concentrating on developing novel treatments, such as mRNA therapeutics, to boost treatment effectiveness and address the fundamental genetic origin of OTC deficiency. mRNA therapeutics constitute a category of treatments that employ messenger RNA (mRNA) to direct cells to create specific proteins for therapeutic goals. These therapies capitalize on the body’s innate protein synthesis processes to treat conditions including genetic disorders, infectious diseases, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a US-based biotechnology company, obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA) for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency. This designation seeks to hasten the drug’s development and evaluation process, potentially offering advantages like more frequent FDA interactions and a priority review. ARCT-810 is formulated to enable patients with OTC deficiency, a urea cycle disorder, to generate functional OTC enzyme in their liver cells, thereby resolving the underlying cause of the condition and possibly enhancing their quality of life.

Which Global Companies Are Actively Competing In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

Major companies operating in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

Read the full ornithine transcarbamylase deficiency (otc deficiency) market report here:

https://www.thebusinessresearchcompany.com/report/ornithine-transcarbamylase-deficiency-otc-deficiency-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (otc deficiency) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp

Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2026, By The Business Research Company

Oryzanol Global Market Report

https://www.thebusinessresearchcompany.com/report/oryzanol-global-market-report

Orthobiologics Global Market Report

https://www.thebusinessresearchcompany.com/report/orthobiologics-global-market-report

Auditing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/auditing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model